Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome

被引:16
|
作者
Harambat, Jerome [1 ]
Godron, Astrid [1 ]
Ernould, Sandrine [1 ]
Rigothier, Claire [2 ]
Llanas, Brigitte [1 ]
Leroy, Sandrine [3 ,4 ]
机构
[1] Ctr Hosp Univ Bordeaux, Ctr Reference Malad Renales Rares Sud Ouest, Serv Pediat, F-33076 Bordeaux, France
[2] Ctr Hosp Univ Bordeaux, Ctr Reference Malad Renales Rares Sud Ouest, Serv Nephrol, F-33076 Bordeaux, France
[3] Univ Oxford, Ctr Stat Med, Oxford, England
[4] Inst Pasteur, Epidemiol Emerging Dis Unit, Paris, France
关键词
Idiopathic nephrotic syndrome; Steroids; Immunosuppressive therapy; Prediction model; INITIAL TREATMENT; CHILDREN; CYCLOSPORINE; DEPENDENCY; CYCLOPHOSPHAMIDE; PREDNISONE;
D O I
10.1007/s00467-012-2365-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
About half of children with steroid-sensitive idiopathic nephrotic syndrome (INS) will develop steroid dependency or a frequently relapsing course requiring steroid-sparing agents (SSA). Because of the adverse effects of prolonged steroid treatment, the early identification of children at high risk of requiring SSA may be a useful diagnostic tool to tailor the therapeutic strategy. The aim of this study was to identify predictors of the need for SSA and derive a predictive model. This was a retrospective hospital-based cohort study which included all children with steroid-responsive INS followed for at least 4.5 months. Cox regression modeling and decision curve analysis were performed. A total of 120 children (81 boys) with INS were included and followed up for a median time of 6.7 (range 0.4-24.1) years. Median age at diagnosis was 3.4 years. Seventy-two (60 %) children required a SSA after a median time of 10 months following initial diagnosis. Male children, age at disease onset, methylprednisolone pulse use, and time to achieve first remission were significantly associated with the outcome. Time to achieve remission only remained significant after adjustment: hazard ratio (HR) = 1.9 [95 % confidence interval (CI) 1.5-2.5] if considered as a continuous variable, and HR = 4.1 (95 % CI 1.9-8.6) when dichotomized using the 9-day threshold. The area under the receiver operating curve of the related predictive model was 0.81 (95 % CI 0.74-0.89), and the decision curve analysis demonstrated that this model performed better than any other strategy. Time to first remission is a strong predictor of the need for SSA in pediatric INS. Further prospective and impact studies are warranted to confirm the accuracy and benefit of our prediction model.
引用
收藏
页码:631 / 638
页数:8
相关论文
共 50 条
  • [41] Omalizumab as a Steroid-Sparing Agent in Chronic Eosinophilic Pneumonia
    Kaya, Hatice
    Gumus, Seyfettin
    Ucar, Ergun
    Aydogan, Mehmet
    Musabak, Ugur
    Tozkoparan, Ergun
    Bilgic, Hayati
    [J]. CHEST, 2012, 142 (02) : 513 - 516
  • [42] Case of Anakinra as a Steroid-Sparing Agent for Gout Inflammation
    Gratton, Sarah B.
    Scalapino, Kenneth J.
    Fye, Kenneth H.
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09): : 1268 - 1270
  • [43] CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent
    Thebault, Simon
    Bergman, Hailey
    Atkins, Harold L.
    Freedman, Mark S.
    Brooks, John
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (01):
  • [44] Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria
    Iweala, Onyinye I.
    Copenhaver, Christopher
    Wu, Eveline Y.
    Moran, Timothy P.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 120 (01) : 102 - 104
  • [45] Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes
    Panch, Sandhya R.
    Bozik, Michael E.
    Brown, Thomas
    Makiya, Michelle
    Prussin, Calman
    Archibald, Donald G.
    Hebrank, Gregory T.
    Sullivan, Mary
    Sun, Xiaoping
    Wetzler, Lauren
    Ware, JeanAnne
    Fay, Michael P.
    Dunbar, Cynthia E.
    Dworetzky, Steven I.
    Khoury, Paneez
    Maric, Irina
    Klion, Amy D.
    [J]. BLOOD, 2018, 132 (05) : 501 - 509
  • [46] Topical cyclosporin A as a steroid-sparing agent for ocular rosacea
    Ong, Hon Shing
    Patel, Krishna V.
    Dart, John K.
    Prstegaard, Morten
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95 (02) : E158 - E159
  • [47] Early Initiation of Steroid-sparing Drugs in Idiopathic Pulmonary Hemosiderosis
    Pal, Priyankar
    De, Hriday
    Giri, Prabhas Prasun
    Ganguly, Nupur
    Mandal, Alolika
    [J]. INDIAN PEDIATRICS, 2019, 56 (01) : 73 - 74
  • [48] Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children
    Lucky, AW
    Leach, AD
    Laskarzewski, P
    Wenck, H
    [J]. PEDIATRIC DERMATOLOGY, 1997, 14 (04) : 321 - 324
  • [49] Patch testing: Another steroid-sparing agent to consider in children
    Jacob, Sharon E.
    Burk, Cynthia J.
    Connelly, Elizabeth Alvarez
    [J]. PEDIATRIC DERMATOLOGY, 2008, 25 (01) : 81 - 87
  • [50] Chlorambucil is a safe and effective steroid-sparing agent in bullous pemphigoid
    Chave, TA
    Shah, DS
    Mortimer, NJ
    Hutchinson, PE
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 : 52 - 52